PharmExec Picks:
Having trouble viewing this e-mail? Click here.
feed back

Update My Profile | Advertise With Us | Visit PharmExec.com |
PRINT SUBSCRIBE | DIGITAL SUBSCRIBE


Pharm Exec Picks is a biweekly eletter that delivers the most popular news and articles from the pharma space and highlights what's trending on social media.

Top 5 Stories :
Pharm Exec's 2015 Emerging Pharma Leaders Slide Show
This year's Pharm Exec list of 17 leaders is ripe with the diversified backgrounds and skills required to advance to the “c-suite” in a new era of change for the industry.
Read more
Pharm Exec's 2015 Pharma 50 Slide Show
Our annual Pharma 50 listing is clear proof that once-small and midsize biopharma companies are moving up to join the top ranks of big Pharma.
Read more

Pssst... You're an Underdog. Start Behaving Like One
Increasing competition in virtually every therapeutic category; movement to outcomes-based measurement; price pressure from payers; rising patient influence; and decreasing authority of individual physicians
Read more
“Rx” for the Latest SCOTUS Decision on Obamacare
For the second time in three years, the Supreme Court of the United States (SCOTUS) has weighed in on key aspects of the 2010 Obamacare law. In this latest case, the Court has determined that regardless of whether or not a state has set up a State Exchange, which was a key element of the original Obamacare concept.
Read more

The Salix-Valeant Acquisition: “It's Just a Game”
In mergers and acquisitions, there's always a winner and a loser. The question of which company's culture will prevail, the acquirer or the acquired, looms large as soon as a deal is struck.
Read more
Sponsored
Patient adherence in Germany - benefit vs. cost-containment
On Demand
Join Joanne Thiele, Market Access Project Manager from Quintiles Germany and Hans Holger Bleβ, Director of Health Services Research department at IGES Institut GmbH as they discuss the importance of patient adherence programs in Germany.
Register for free
Trending on Social Media :
The Challenge of Forecasting Biosimilars
 The introduction of biologic medicines revolutionized treatment in several key therapeutic areas, including oncology, diabetes and various inflammatory diseases. The landscape for biologics will change dramatically in the next decade as many products – more than $60 billion in worldwide sales – lose their market exclusivity.
Read more
Optimizing Clinical Trials Using Electronic Measurement and Analysis of Drug Adherence
Drug development has never before been so difficult, time consuming and expensive. Accuracy in clinical trials, therefore, is a priority.
Read more
Greece: More Than Next Week's Medicine Supply At Risk
 There are some evident challenges for pharma in the ongoing Greek crisis. But, writes Reflector, there are some less evident challenges which may, over time, prove to be more difficult for the industry to cope with.
Read more
Follow Us